Related Experiment Videos
Chylothorax in children after congenital heart surgery
Shu-yan Chan1, Wendy Lau, Wilfred H S Wong
1Division of Paediatric Cardiology, Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, China.
Insights
Postoperative chylothorax in children after heart surgery is challenging to manage. Octreotide therapy, alongside nutritional modifications, shows promise as an effective adjunctive treatment, improving outcomes.
Area of Science:
- Pediatric Cardiology
- Thoracic Surgery
- Critical Care Medicine
Background:
- Postoperative chylothorax management in pediatric congenital heart surgery patients lacks a definitive strategy.
- This study reviews institutional experience with chylothorax management in this population.
Purpose of the Study:
- To evaluate the effectiveness of different management strategies for postoperative chylothorax in children undergoing congenital heart surgery.
- To assess the role of octreotide therapy as an adjunctive treatment.
Main Methods:
- Retrospective review of 51 pediatric patients diagnosed with postoperative chylothorax between 1981 and 2004.
- Analysis of patient responses to nutritional modifications, octreotide therapy, and surgical interventions.
Main Results:
- The prevalence of chylothorax was 0.85%, with a median onset of 9 days post-operation.
- Octreotide therapy was initiated in 18 patients (2000-2004 cohort), with 83% responding favorably.
- The duration of chyle output was significantly longer following Fontan-type procedures.
Conclusions:
- Octreotide therapy is a valuable addition to the management of pediatric postoperative chylothorax.
- Nutritional modifications remain a primary treatment, with octreotide used as an adjunctive therapy when needed.
Background:
A definitive management strategy for postoperative chylothorax remains elusive. We reviewed our experience in the management of chylothorax in children after congenital heart surgery.
Methods:
The case records of 51 patients, with a median age of 11 months (range, 4 days to 19.6 years), diagnosed to have postoperative chylothorax between 1981 and 2004 were reviewed. The responses of patients to nutritional modifications, octreotide therapy, and surgical interventions were noted.
Results:
The prevalence of postoperative chylothorax, which developed at a median of 9 days after operation (range, 0 to 24 days), was 0.85% (51 of 5,995). Four patients died, and among the 47 survivors the median duration and total volume of chylous drainage was 15 days (range, 1 to 89 days) and 156 mL/kg (range, 3 to 6,476), respectively. The duration of chyle output was significantly longer after the Fontan-type procedures (p = 0.0006). Twenty-one patients were diagnosed between 1981 and 1999 and managed by nutritional modifications, 2 of whom required further surgical interventions. Of the 30 patients diagnosed between 2000 and 2004, 12 responded to nutritional modifications alone while 18 were started on octreotide therapy at a median of 19.5 days (range, 7 to 35 days) after the onset of chylothorax. Fifteen of the 18 (83%) patients responded to octreotide therapy at 15.3 +/- 5.5 days after starting octreotide, while 3 required further surgical interventions. None developed side effects from octreotide therapy.
Conclusions:
Octreotide has been incorporated into the management algorithm of postoperative chylothorax and appears to be a useful adjunctive therapy.
Related Concept Videos
Pneumothorax-II
Clinical Manifestations:
Endoscopic Studies II: Thoracocentesis
Description
Excess pleural fluid or air may accumulate in some respiratory disorders in the thoracic cavity. To treat pleural effusion, a physician conducts thoracentesis by carefully piercing the chest wall and entering...
Pulmonary Cycle: Exhalation
Pneumothorax-I
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pneumothorax II: Pathophysiology
Flail Chest-II
Assessment:
1. Clinical Evaluation:
History: